Prelude Therapeutics Incorporated

Healthcare · Biotechnology · United States

Last price 4.1 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 422.28M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCel...